Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice.

ABSTRACT:

Background

Immune checkpoint inhibitor therapy has revolutionized the clinical management of a diverse range of cancer types, including advanced cutaneous melanoma. While immunotherapy targeting the PD-1/PD-L1 system has become standard of care, overall response rates remain unsatisfactory for most patients and there are no approved small molecule inhibitors of the PD-1/PD-L1 system. Flubendazole (FLU) is an anthelmintic that has been used to treat worm infections in humans and animals for decades.

Methods

Here we tested the anti-cancer activity of systemically delivered FLU with suppression of PD-1 in immunocompetent mice.

Results

In C57BL/6J mice bearing subcutaneous B16F10 melanoma, FLU reduced both tumor growth and PD-1 protein levels without affecting levels of P

SUBMITTER: Li Y 

PROVIDER: S-EPMC10349441 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature